James Wassil
Overview
Explore the profile of James Wassil including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wassil J, Sisti M, Fairman J, Davis M, Fierro C, Bennett S, et al.
Lancet Infect Dis
. 2023 Dec;
24(3):308-318.
PMID: 38061367
Background: Despite substantial reductions in pneumococcal disease with the availability of pneumococcal conjugate vaccines, a significant burden of pneumococcal disease remains due to the diversity of serotypes combined with serotype...
2.
Jansen K, Gruber W, Simon R, Wassil J, Anderson A
Environ Chem Lett
. 2021 Oct;
19(6):4031-4062.
PMID: 34602924
At present, the dramatic rise in antimicrobial resistance (AMR) among important human bacterial pathogens is reaching a state of global crisis threatening a return to the pre-antibiotic era. AMR, already...
3.
Fairman J, Agarwal P, Barbanel S, Behrens C, Berges A, Burky J, et al.
Vaccine
. 2021 May;
39(23):3197-3206.
PMID: 33965258
Despite widespread utilization of pneumococcal conjugate vaccines (PCVs) and the resultant disease reduction, the development of PCVs containing additional serotypes remains a public health priority due to serotype replacement and...
4.
Nolan T, ORyan M, Wassil J, Abitbol V, Dull P
Vaccine
. 2015 Jul;
33(36):4437-45.
PMID: 26187261
Vaccination programs employing capsular-based meningococcal vaccines have proved successful in a variety of settings globally since first introduced over 40 years ago. Similar successes have been demonstrated using meningococcal vaccines...
5.
Medini D, Stella M, Wassil J
Vaccine
. 2015 Apr;
33(23):2629-36.
PMID: 25882169
Recently approved in the EU, US, Australia, and Canada, 4CMenB (Bexsero(®), GSK Vaccines) is a multi-component meningococcal B (MenB) vaccine containing 3 surface exposed recombinant proteins (fHbp, NadA, and NHBA)...
6.
McIntosh E, Carey V, Toneatto D, Dull P, Wassil J
Ther Adv Vaccines
. 2015 Jan;
3(1):13-23.
PMID: 25553243
In countries with established programmes for vaccination of infants, toddlers and adolescents with meningococcal conjugate vaccines, serogroup B invasive meningococcal disease remains the major cause of septicaemia and meningitis in...
7.
Rappuoli R, Wassil J, Bonefeld L, Porter J
BMJ
. 2014 Nov;
349:g6759.
PMID: 25394622
No abstract available.
8.
ORyan M, Stoddard J, Toneatto D, Wassil J, Dull P
Drugs
. 2013 Dec;
74(1):15-30.
PMID: 24338083
Recently approved in Europe and Australia, the multi-component meningococcal B vaccine, 4CMenB (Bexsero®, Novartis Vaccines and Diagnostics), contains three surface-exposed recombinant proteins (fHbp, NadA, and NHBA) and New Zealand strain...
9.
Wassil J, Huels J, Narasimhan V
Vaccine
. 2013 Aug;
32(25):2943.
PMID: 23962533
No abstract available.